This is a summary of the European public assessment report (EPAR) for Ledaga. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ledaga. For practical information about using Ledaga, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Therapeutic Area (MeSH)
N/AATC Code
L01AA05
ATC Item
chlormethine
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/AEMA Name
Ledaga
Medicine Name
Ledaga
Aliases
N/ANo risk management plan link.
